- List
- By Topic
- On Map
- Search Details

Recruiting, Not yet recruiting, Available Studies | "Testicular Neoplasms"
Need help? See RSS Feeds
Choose a feed type:

Recruiting, Not yet recruiting, Available Studies | "Testicular Neoplasms" (51 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT02229916 | Recruiting | Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS |
|
Observational |
|
Other |
|
|
6900 | Male | 18 Years and older (Adult, Senior) | NCT02229916 | SG359/13 | SAG TCCS | December 2013 | September 2019 | September 2029 | September 3, 2014 | July 19, 2017 |
|
|||
2 | NCT03436901 | Recruiting | Whole Body MRI With DWI for Monitoring Patients Treated for Testicular Cancer Stage II-III |
|
|
Interventional | Not Applicable |
|
Other |
|
|
78 | Male | 18 Years and older (Adult, Senior) | NCT03436901 | VEK RM 1-10-72-179-17 | TENY | February 19, 2018 | September 2020 | September 2020 | February 19, 2018 | February 22, 2018 |
|
|
3 | NCT02572934 | Recruiting | Health Status and Burden of Late Effects in Very Long-term Testicular Cancer Survivors (STANDBY-study) |
|
Observational |
|
Other |
|
|
280 | Male | 18 Years to 70 Years (Adult, Senior) | NCT02572934 | NL53126.042.15 | STANDBY | August 2015 | September 2018 | September 2018 | October 9, 2015 | November 13, 2017 |
|
|||
4 | NCT02890030 | Recruiting | The Platinum Study Comparison Group |
|
|
Observational |
|
Other |
|
|
109 | Male | 18 Years to 55 Years (Adult) | NCT02890030 | IRB No. 1604502652 | May 2015 | December 2017 | December 2019 | September 7, 2016 | September 28, 2017 |
|
|||
5 | NCT03360994 | Recruiting | WATChmAN Virtual Testicular Cancer Clinic |
|
|
Interventional | Not Applicable |
|
Other |
|
|
144 | Male | 18 Years and older (Adult, Senior) | NCT03360994 | 17-5366 | December 15, 2017 | December 1, 2024 | December 1, 2024 | December 4, 2017 | December 29, 2017 |
|
||
6 | NCT03339635 | Not yet recruiting | Short-term Testosterone Replacement in Testicular Cancer Survivors |
|
|
Interventional | Phase 2 |
|
Other |
|
|
40 | Male | 18 Years to 55 Years (Adult) | NCT03339635 | 201600107 | January 2018 | January 2020 | January 2020 | November 13, 2017 | November 13, 2017 |
|
||
7 | NCT02341989 | Recruiting | Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer |
|
|
Interventional | Phase 3 |
|
Other |
|
|
348 | Male | 18 Years to 60 Years (Adult) | NCT02341989 | 2014/2012 2014-004075-23 |
SWENOTECA-ABC | April 2015 | December 2020 | December 2020 | January 19, 2015 | October 25, 2017 |
|
|
8 | NCT00034424 | Recruiting | Cause of Familial Testicular Cancer |
|
Observational |
|
NIH |
|
|
1750 | All | 12 Years to 100 Years (Child, Adult, Senior) | NCT00034424 | 020178 02-C-0178 |
July 1, 2002 | April 29, 2002 | December 28, 2017 |
|
||||||
9 | NCT02860819 | Recruiting | Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
43 | Male | 18 Years and older (Adult, Senior) | NCT02860819 | GCTSK004 | July 2016 | March 2018 | December 2018 | August 9, 2016 | January 4, 2018 |
|
||
10 | NCT02573584 | Recruiting | Vascular Fingerprint Validation Study |
|
Observational |
|
Other |
|
|
178 | Male | 18 Years to 50 Years (Adult) | NCT02573584 | 201500864 | October 2015 | December 2017 | December 2017 | October 12, 2015 | June 2, 2017 |
|
||||
11 | NCT02276430 | Recruiting | TACkLE Study - Tackling Adverse Chemotherapy-associated Late Effects |
|
|
Observational |
|
Other |
|
|
900 | Male | 18 Years to 75 Years (Adult, Senior) | NCT02276430 | KWF2011-5209 NL45655.042.13 |
TACkLE | July 2014 | June 2018 | June 2018 | October 28, 2014 | November 13, 2017 |
|
||
12 | NCT02099734 | Recruiting | Germ Cell Tumor and Testicular Tumor DNA Registry |
|
|
Observational |
|
Other |
|
|
1000 | All | 18 Years and older (Adult, Senior) | NCT02099734 | 14-016 | January 2014 | January 2019 | January 2019 | March 31, 2014 | February 1, 2018 |
|
|||
13 | NCT02991209 | Recruiting | Study of Testosterone vs Placebo in Testicular Cancer Survivors |
|
|
Interventional | Phase 2 Phase 3 |
|
Other |
|
|
70 | Male | 18 Years to 65 Years (Adult) | NCT02991209 | 010815Testis | Einstein | November 2016 | August 2019 | December 2019 | December 13, 2016 | January 11, 2017 |
|
|
14 | NCT02478502 | Recruiting | Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
29 | Male | 18 Years and older (Adult, Senior) | NCT02478502 | 2012/1627 b 2012-004418-32 |
June 2015 | December 2017 | June 2018 | June 23, 2015 | June 20, 2017 |
|
||
15 | NCT02304575 | Recruiting | Quality of Life Among Testicular Cancer Survivors |
|
|
Observational |
|
Other |
|
|
330 | Male | 18 Years to 75 Years (Adult, Senior) | NCT02304575 | 0482-14-RMC | January 2015 | November 2018 | November 2018 | December 2, 2014 | October 17, 2017 |
|
|||
16 | NCT02433197 | Recruiting | Effectiveness of an Individualized Program of Muscular Strength and Endurance Program for Improving Germ Cell Cancer |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
20 | All | 18 Years to 45 Years (Adult) | NCT02433197 | FCCSS-UMA_04-15 | EFICATEST | December 2015 | April 2016 | December 2017 | May 4, 2015 | March 31, 2017 |
|
|
17 | NCT00936936 | Recruiting | High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors |
|
|
Interventional | Phase 2 |
|
Other |
|
|
67 | All | 12 Years to 65 Years (Child, Adult) | NCT00936936 | 2008-0378 NCI-2011-01631 |
June 2009 | June 2019 | June 2019 | July 10, 2009 | September 15, 2017 |
|
||
18 | NCT03403777 | Recruiting | Avelumab in Refractory Testicular Germ Cell Cancer. |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
43 | Male | 18 Years and older (Adult, Senior) | NCT03403777 | NCISlovakia | November 15, 2017 | December 31, 2019 | December 31, 2020 | January 19, 2018 | January 25, 2018 |
|
||
19 | NCT01883518 | Recruiting | Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
48 | All | 18 Years and older (Adult, Senior) | NCT01883518 | MC-01-2013 | ADCVCTAST | June 2013 | September 2017 | September 2017 | June 21, 2013 | February 15, 2017 |
|
|
20 | NCT03426865 | Recruiting | Role of Axumin PET Scan in Germ Cell Tumor |
|
|
Interventional | Phase 2 |
|
Other |
|
|
10 | Male | 18 Years and older (Adult, Senior) | NCT03426865 | 032017-051 | TESTPET | February 15, 2018 | December 31, 2018 | January 31, 2019 | February 8, 2018 | February 8, 2018 |
|
|
21 | NCT02689219 | Recruiting | Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors |
|
|
Interventional | Phase 2 |
|
Other |
|
|
58 | All | 18 Years and older (Adult, Senior) | NCT02689219 | IUSCC-0568 | March 9, 2016 | December 31, 2018 | December 31, 2019 | February 23, 2016 | February 19, 2018 |
|
||
22 | NCT03448822 | Not yet recruiting | Sentinel Lymph Node Procedure in Testicular Germ Cell Tumour |
|
|
Observational |
|
Other |
|
|
76 | Male | 18 Years and older (Adult, Senior) | NCT03448822 | M18TGC | SENATOR | April 1, 2018 | April 1, 2020 | April 1, 2026 | February 28, 2018 | February 28, 2018 | |||
23 | NCT02797626 | Recruiting | Trial to Evaluate Progression Free Survival With Primary Retroperitoneal Lymph-node Dissection (pRPLND) Only in Patients With Seminomatous Testicular Germ Cell Tumors With Clinical Stage IIA/B (PRIMETEST) |
|
|
Interventional | Phase 2 |
|
Other |
|
|
30 | Male | Child, Adult, Senior | NCT02797626 | 2015053664 | June 2016 | June 2021 | June 2021 | June 13, 2016 | June 13, 2016 |
|
||
24 | NCT02784054 | Recruiting | Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor |
|
|
Interventional | Phase 2 |
|
Other |
|
|
25 | All | 3 Years to 30 Years (Child, Adult) | NCT02784054 | 2013-07-146 | April 2014 | March 2018 | May 26, 2016 | May 26, 2016 |
|
|||
25 | NCT02317393 | Recruiting | Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy |
|
|
Interventional | Phase 2 |
|
Other |
|
|
19 | All | 18 Years and older (Adult, Senior) | NCT02317393 | TERMATEP | TERMATEP | December 2014 | March 2020 | March 2020 | December 16, 2014 | January 4, 2018 |
|
|
26 | NCT02303015 | Recruiting | Toxicity Attributed to Genetic Polymorphisms in Testicular Germ Cell Tumor Survivors |
|
Observational |
|
Other |
|
|
4000 | Male | 15 Years and older (Child, Adult, Senior) | NCT02303015 | DaTeCa01 | August 2014 | March 2019 | June 2019 | November 27, 2014 | October 2, 2017 |
|
||||
27 | NCT02115165 | Recruiting | A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
34 | Male | 15 Years and older (Child, Adult, Senior) | NCT02115165 | 2013-000286-36 2012/1950 |
CABA-GCT | May 2014 | May 2017 | May 2020 | April 15, 2014 | June 9, 2016 |
|
|
28 | NCT02109926 | Recruiting | A Case-control Study to Assess the Association Between Environmental, Domestic and Occupational Exposures and the Risk of Testicular Germ Cell Tumor |
|
|
Observational |
|
Other |
|
|
1500 | Male | 18 Years to 44 Years (Adult) | NCT02109926 | TESTIS ET14-004 140184B-12 |
TESTIS | January 2015 | March 30, 2018 | June 2018 | April 10, 2014 | February 9, 2018 |
|
||
29 | NCT00001452 | Recruiting | Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex |
|
Observational |
|
NIH | 99999999 | All | 3 Years and older (Child, Adult, Senior) | NCT00001452 | 950059 95-CH-0059 |
January 24, 1995 | November 4, 1999 | April 20, 2018 |
|
||||||||
30 | NCT02853006 | Recruiting | Study on Fluids Associated to Lung Cancer |
|
|
Interventional | Not Applicable |
|
Other |
|
|
200 | All | 18 Years and older (Adult, Senior) | NCT02853006 | 38RC15.099 | ECTOPIC/MUTAS | June 2015 | June 2019 | June 2019 | August 2, 2016 | August 2, 2016 |
|
|
31 | NCT02994758 | Recruiting | Development of Diagnostics and Treatment of Urological Cancers |
|
|
Interventional | Not Applicable |
|
Other |
|
|
100 | All | 18 Years and older (Adult, Senior) | NCT02994758 | None yet | DEDUCER | November 27, 2017 | December 2020 | December 2020 | December 16, 2016 | December 14, 2017 |
|
|
32 | NCT03232541 | Recruiting | The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting |
|
|
Interventional | Not Applicable |
|
Other |
|
|
288 | All | 18 Years and older (Adult, Senior) | NCT03232541 | Emesis 001 | September 1, 2017 | June 2019 | June 2019 | July 28, 2017 | March 29, 2018 |
|
||
33 | NCT02900248 | Recruiting | CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice |
|
|
Observational |
|
Other |
|
|
100000 | All | 18 Years and older (Adult, Senior) | NCT02900248 | N1OR | N1 | October 2, 2017 | October 2021 | October 2024 | September 14, 2016 | October 4, 2017 |
|
||
34 | NCT01037790 | Recruiting | PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER |
|
|
Interventional | Phase 2 |
|
Other |
|
|
205 | All | 18 Years and older (Adult, Senior) | NCT01037790 | UPCC 03909 NCI-2009-01467 |
October 2009 | October 2016 | December 23, 2009 | August 25, 2016 |
|
|||
35 | NCT03452774 | Recruiting | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry |
|
|
Observational |
|
Industry |
|
|
1500 | All | Child, Adult, Senior | NCT03452774 | SYNERGY-AI | January 1, 2018 | December 2021 | December 2022 | March 2, 2018 | March 2, 2018 |
|
|||
36 | NCT03133286 | Recruiting | Radiotherapy Assessments During Intervention ANd Treatment (RADIANT) |
|
Observational |
|
Industry / NIH |
|
|
500 | All | 18 Years and older (Adult, Senior) | NCT03133286 | DXT-RADTOX-AC03 HHSN261201600051C |
RADIANT | April 6, 2017 | September 6, 2018 | September 6, 2018 | April 28, 2017 | May 4, 2017 |
|
|||
37 | NCT02012699 | Recruiting | Integrated Cancer Repository for Cancer Research |
|
Observational |
|
Other |
|
|
9999 | All | 19 Years to 110 Years (Adult, Senior) | NCT02012699 | UNMC 253-13 | iCaRe2 | November 2013 | December 2099 | December 2099 | December 16, 2013 | May 9, 2017 |
|
|||
38 | NCT01434355 | Recruiting | DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings |
|
|
Observational |
|
Other / NIH |
|
|
932 | All | up to 19 Years (Child, Adult) | NCT01434355 | AEPI10N1 NCI-2011-03464 COG-AEPI10N1 |
November 2011 | August 2018 | September 14, 2011 | October 9, 2017 |
|
||||
39 | NCT03158064 | Recruiting | Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors |
|
|
Interventional | Phase 2 |
|
Other |
|
|
29 | All | 18 Years and older (Adult, Senior) | NCT03158064 | 17-160 | May 15, 2017 | November 2019 | November 2019 | May 17, 2017 | September 25, 2017 |
|
||
40 | NCT02834013 | Recruiting | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
|
|
Interventional | Phase 2 |
|
NIH |
|
|
707 | All | 18 Years and older (Adult, Senior) | NCT02834013 | NCI-2016-01041 S1609 U10CA180888 |
January 13, 2017 | August 31, 2020 | July 15, 2016 | April 17, 2018 |
|
|||
41 | NCT02375204 | Recruiting | Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors |
|
|
Interventional | Phase 3 |
|
Other / NIH |
|
|
420 | Male | 14 Years and older (Child, Adult, Senior) | NCT02375204 | A031102 U10CA180821 NCI-2014-01696 |
March 2015 | June 2024 | March 2, 2015 | April 9, 2018 |
|
|||
42 | NCT01042522 | Recruiting | Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors |
|
|
Interventional | Phase 2 |
|
Other / NIH |
|
|
128 | Female | 18 Years and older (Adult, Senior) | NCT01042522 | GOG-0264 NCI-2011-02000 CDR0000662814 U10CA180868 U10CA027469 |
February 8, 2010 | January 2, 2024 | January 5, 2010 | February 16, 2018 |
|
|||
43 | NCT03382158 | Recruiting | International PPB Registry for PPB, DICER1 and Associated Conditions |
|
Observational |
|
Other |
|
|
100 | All | Child, Adult, Senior | NCT03382158 | FDAAA | December 6, 2016 | December 6, 2023 | December 6, 2026 | December 22, 2017 | December 22, 2017 |
|
||||
44 | NCT01247597 | Recruiting | DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study |
|
Observational |
|
NIH |
|
|
1500 | All | up to 100 Years (Child, Adult, Senior) | NCT01247597 | 110034 11-C-0034 |
November 23, 2010 | November 24, 2010 | April 17, 2018 |
|
||||||
45 | NCT00565903 | Recruiting | Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome |
|
Observational |
|
Other |
|
|
2000 | All | up to 95 Years (Child, Adult, Senior) | NCT00565903 | 05-0192 / 201012830 | PPB | March 2005 | December 2018 | December 2020 | November 30, 2007 | July 19, 2017 |
|
|||
46 | NCT03081923 | Recruiting | Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
120 | Male | 18 Years to 75 Years (Adult, Senior) | NCT03081923 | INT123-16 | APACHE | February 1, 2017 | February 2019 | August 2019 | March 16, 2017 | March 16, 2017 |
|
|
47 | NCT00432094 | Recruiting | Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors |
|
|
Interventional | Phase 2 |
|
Other |
|
|
25 | All | 10 Years to 69 Years (Child, Adult, Senior) | NCT00432094 | 2006LS032 UMN-MT2005-21 UMN-0608M90586 |
December 19, 2006 | January 2019 | January 2019 | February 7, 2007 | February 13, 2018 |
|
||
48 | NCT03452436 | Recruiting | Testosterone, Cognition, Ageing, and Cancer |
|
Observational |
|
Other |
|
|
120 | Male | 18 Years and older (Adult, Senior) | NCT03452436 | TCAC | February 12, 2018 | February 1, 2020 | February 1, 2020 | March 2, 2018 | March 5, 2018 |
|
||||
49 | NCT02223052 | Recruiting | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
90 | All | 18 Years and older (Adult, Senior) | NCT02223052 | CC-486-CAGEN-001 | October 27, 2014 | March 19, 2019 | March 19, 2019 | August 22, 2014 | March 2, 2018 |
|
||
50 | NCT02750995 | Recruiting | Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML |
|
|
Interventional | Phase 1 |
|
Other |
|
|
15 | All | 18 Years and older (Adult, Senior) | NCT02750995 | AZACTA | AZACTA | April 2016 | April 2020 | September 2020 | April 26, 2016 | September 1, 2017 |
|
† Study has passed its completion date and status has not been verified in more than two years.